You are viewing: Brazil Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Brazil Nuclear Medicine Market was valued at $259.2 Million in 2025 and projected to reach to $395.7 Million by 2030, representing a compound annual growth rate of 8.8%. Brazil's nuclear medicine market is positioned for sustained growth through 2030, driven by increasing healthcare modernization and rising demand for advanced diagnostic imaging solutions.

Brazil Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Brazil Nuclear Medicine Market Trends and Insights

  • This 8.8% compound annual growth rate reflects Brazil's increasing adoption of diagnostic imaging and therapeutic nuclear medicine procedures across major healthcare centers.
  • Brazil's market expansion is driven by rising healthcare investments, growing prevalence of chronic diseases, and improved access to nuclear medicine facilities in urban and emerging regional markets. The Brazilian nuclear medicine sector benefits from a well-established healthcare infrastructure and growing demand for advanced diagnostic capabilities.
  • Brazil's market growth outpaces many regional peers, supported by government healthcare initiatives and private sector investments in medical technology.
  • Between 2025 and 2030, Brazil is expected to see enhanced adoption of PET-CT imaging, radiopharmaceutical therapies, and nuclear cardiology procedures, positioning the country as a key market within Latin America's nuclear medicine landscape..

Key Market Statistics

  • CAGR (2025-2030) 8.8% CAGR
  • Market Size, 2025 ~USD 259.2 Million
  • Forecast, 2030 ~USD 395.7 Million
  • Country Brazil

Brazil Nuclear Medicine Market Overview

Market Valuation :

Brazil's nuclear medicine market is valued at USD 259.2 million in 2025, with projections reaching USD 395.7 million by 2030, representing a robust 8.8% CAGR over the forecast period.

Healthcare Infrastructure Expansion :

Major Brazilian healthcare centers are increasingly adopting diagnostic imaging and therapeutic nuclear medicine procedures, supported by rising government and private sector healthcare investments.

Growth Drivers :

Brazil's market expansion is fueled by improved access to nuclear medicine facilities, growing prevalence of chronic diseases, and enhanced reimbursement policies for nuclear diagnostic and therapeutic procedures.

Regional Performance :

Brazil's 8.8% CAGR demonstrates steady market maturation, with significant opportunities in urban centers like São Paulo and Rio de Janeiro where healthcare spending and diagnostic adoption rates are highest.

Brazil Nuclear Medicine Market Dynamics

  • The country's expanding middle class and improved healthcare accessibility are accelerating adoption of nuclear medicine procedures across both public and private healthcare systems.
  • Investment in medical infrastructure and growing awareness of nuclear medicine benefits among healthcare professionals will continue to support market expansion.
  • Additionally, Brazil's regulatory environment is becoming more favorable for nuclear medicine technologies, enabling faster market penetration and innovation in diagnostic and therapeutic applications..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Brazil's nuclear medicine market is valued at USD 259.2 million in 2025, with projected growth to USD 395.7 million by 2030.
    • Brazil demonstrates an 8.8% CAGR, reflecting steady expansion driven by healthcare infrastructure improvements and chronic disease prevalence.
    • Brazil's market benefits from government healthcare initiatives and private sector investments in advanced diagnostic imaging technologies.
    • Brazil is positioned as a leading nuclear medicine market in Latin America, with growing adoption of PET-CT and radiopharmaceutical therapies.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    Brazil Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    BRAZIL: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES21.122.824.626.628.831.133.636.38.1
    DIAGNOSTIC & IMAGING CENTERS59.465.371.87986.995.5105115.29.9
    HOSPITALS132143.3155.7169.1183.6199.2216233.98.5
    OTHER END USERS6.26.67.17.78.38.99.610.37.5
    TOTAL218.6238259.2282.4307.5334.8364.2395.78.8

    Target Audience

    • Medical Device Manufacturers : Manufacturers of nuclear medicine equipment and imaging systems need Brazil-specific market data to assess market potential, plan product launches, and develop distribution partnerships in this growing healthcare market.
    • Healthcare Investors : Investment firms and healthcare funds require detailed Brazil market analysis to evaluate investment opportunities in nuclear medicine facilities, diagnostic centers, and healthcare infrastructure projects.
    • Pharmaceutical Companies : Pharmaceutical firms developing radiopharmaceuticals and nuclear medicine therapeutics need Brazil market insights to guide clinical trial planning, regulatory strategy, and commercial launch timelines.
    • Healthcare Consultants : Management consultants advising healthcare organizations and government agencies require Brazil-specific market intelligence to develop strategic plans and policy recommendations for nuclear medicine expansion.
    • Hospital & Diagnostic Center Operators : Healthcare facility operators need market forecasts and growth drivers to justify capital investments in nuclear medicine departments, equipment upgrades, and service expansion in Brazil.

    Reasons to Buy this Report

    • Market Entry Strategy : Gain comprehensive insights into Brazil's nuclear medicine landscape to develop targeted market entry strategies, identify key stakeholders, and understand competitive positioning in South America's largest healthcare market.
    • Investment Decision Support : Access detailed financial projections and growth metrics to support investment decisions in Brazilian nuclear medicine infrastructure, equipment distribution, and service expansion opportunities through 2030.
    • Competitive Intelligence : Understand Brazil-specific market dynamics, regulatory requirements, and competitive landscape to benchmark performance against local and international players operating in the nuclear medicine sector.
    • Product Development Roadmap : Identify Brazil-specific clinical needs, procedure preferences, and healthcare provider requirements to inform product development, localization strategies, and service offerings tailored to Brazilian market demands.
    • Revenue Forecasting : Utilize accurate market sizing and CAGR data specific to Brazil for precise revenue forecasting, budget allocation, and performance tracking across diagnostic and therapeutic nuclear medicine segments.

    Frequently asked questions

    What is the current size of Brazil's nuclear medicine market?

    Brazil's nuclear medicine market is valued at USD 259.2 million in 2025 and is projected to reach USD 395.7 million by 2030.

    What is the growth rate of Brazil's nuclear medicine market?

    Brazil's nuclear medicine market is growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2030.

    What factors are driving growth in Brazil's nuclear medicine market?

    Brazil's market growth is driven by rising healthcare investments, increasing prevalence of chronic diseases, improved access to nuclear medicine facilities, and government healthcare initiatives supporting advanced diagnostic technologies.

    Which nuclear medicine procedures are most adopted in Brazil?

    Brazil is experiencing growing adoption of PET-CT imaging, radiopharmaceutical therapies, and nuclear cardiology procedures across major healthcare centers.

    How does Brazil's nuclear medicine market compare to other Latin American countries?

    Brazil is positioned as a leading nuclear medicine market in Latin America, with steady growth supported by well-established healthcare infrastructure and significant private and public sector investments.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status